PROTAC ERα Degrader-12

PROTAC ERα Degrader-12 是一种强效且高选择性的 ERα PROTAC 降解剂,对多种野生或突变型 ERα 的乳腺癌细胞系具有抗增殖作用,可阻滞细胞周期并诱导细胞凋亡 (apoptosis),具有出色的抗肿瘤活性,可用于乳腺癌的研究(粉色:ERα 配体 (MS-I24477);蓝色:VHL 配体 (MS-R95960);黑色:连接子 (MS-X47707))。
PROTAC ERα Degrader-12
产品编号: MS-D54138 分子式: C53H83N7O5S 分子量: 930.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PROTAC ERα Degrader-12 是一种强效且高选择性的 ERα PROTAC 降解剂,对多种野生或突变型 ERα 的乳腺癌细胞系具有抗增殖作用,可阻滞细胞周期并诱导细胞凋亡 (apoptosis),具有出色的抗肿瘤活性,可用于乳腺癌的研究(粉色:ERα 配体 (MS-I24477);蓝色:VHL 配体 (MS-R95960);黑色:连接子 (MS-X47707))。

生物实验数据

生物活性 PROTAC ERα Degrader-12 is a potent and highly selective ERα PROTAC degrader that exerts antiproliferative effects on multiple wild-type or mutant ERα breast cancer cell lines, induces cell cycle arrest and apoptosis (apoptosis), exhibits excellent antitumor activity, and can be used for breast cancer research (pink: ERα ligand (MS-I24477); blue: VHL ligand (MS-R95960); black: linker (MS-X47707)).
IC50 & Target

ERα

 

VHL

 

体外研究
(In Vitro)

PROTAC ERα Degrader-12 (Compound CP03) (0.1-10 μM, 24 h) 在 MCF-7 细胞中显示出显著的降解活性,其 DC50 值为 1.02 μM。
PROTAC ERα Degrader-12 (0.01-100 μM, 24 h) 在 MCF-7 细胞中具备显著的抗肿瘤活性 (IC50 = 0.17 μM)。
PROTAC ERα Degrader-12 在人肝微粒体和血浆中表现出显著的稳定性,其血浆蛋白结合率为 97.8%。
PROTAC ERα Degrader-12 (1-5 μM, 48 h) 在 MCF-7 细胞中可阻滞细胞周期 (G1),并诱导细胞出现大量死亡和损伤。

Western Blot Analysis

Cell Line: MCF-7, MDA-MB-321, MCF-7Y537S, MCF-7D538G, MCF-7EGFR, and LCC-2 cell lines
Concentration: 0.1, 0.2, 1, 2, 5, 10 μM
Incubation Time: 24 h
Result: Effectively induced ERα degradation in a dose-dependent manner in MCF-7 cells.
Efficiently reduced the ErαMUT levels in both the MCF-7Y537S and MCF-7D538G cell lines with DC50 values of 0.83 and 0.55 μM, respectively.
Showed high degradation potency for ERα in MCF-7EGFR and LCC-2 cell lines, with DC50 values of 0.13 and 1.40 μM, respectively.

Western Blot Analysis

Cell Line: MCF-7
Concentration: 2 μM
Incubation Time: 24 h
Result: Was markedly suppressed in the presence of CoA-1 or CoA-2.

Cell Viability Assay

Cell Line: MCF-7, MDA-MB-321, MCF-7Y537S, MCF-7D538G, MCF-7EGFR, and LCC-2 cell lines
Concentration: 0.01, 0.1, 1, 10, 100 μM
Incubation Time: 24 h
Result: Had no notable inhibitory influence on cell growth in the ER-negative cell line MDA-MB-231 at concentrations exceeding 100 μM.
Exhibited excellent antiproliferative activity in MCF-7 Y537S , MCF-7D538G , and MCF-7EGFR, with IC50 values that were 10.3-, 19.4-, and 58.0-fold higher than those of Ful, respectively.
Displayed enhanced antiproliferative efficacy against Tamoxifen (MS-L29547)-resistant LCC-2 cells, with an IC50 value that was 8.04-fold higher than that of Fulvestrant (MS-S35194).

RT-PCR

Cell Line: MCF-7
Concentration: 0.1, 1 μM
Incubation Time: 24 h
Result: Had no discernible impact on the mRNA of ERα expression.

Apoptosis Analysis

Cell Line: MCF-7, MDA-MB-321, MCF-7Y537S, MCF-7D538G, MCF-7EGFR, and LCC-2 cell lines
Concentration: 1, 5 μM
Incubation Time: 48 h
Result: Induced substantial cellular death and damage in a concentration-dependent manner.
Effectively halted the cell cycle progression in the G1 phase.
体内研究
(In Vivo)

PROTAC ERα Degrader-12 (Compound CP03) (1-4 mg/kg, i.p., 每隔一天, 共 26 或 33 天) 在小鼠 MCF-7 和 LCC-2 肿瘤异种移植模型中具有显著的抗肿瘤效果。

Animal Model: MCF-7 and LCC-2 tumor xenograft models established in female BALB/c nude mice (15-18 g, 5 weeks old)
Dosage: 1, 2, 4 mg/kg
Administration: Intraperitoneal injection (i.p.), every other day, for 26 or 33 days.
Result: Showed significant tumor growth inhibitory activity at 2 mg/kg.
Had no significant host toxicity as monitored by changes in the body weight.
Almost completely inhibited tumor growth on day 33 at a dose of 2 or 4 mg/kg.
Effectively induced significant degradation of ERα with 2 mg/kg.

化学信息

分子量 930.34
分子式 C53H83N7O5S

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础